📈 Profit Update on Synopsys (SNPS): How the $460 Strike Call Doubled in Value

When we first released our analysis on Synopsys (SNPS), we emphasized the importance of disciplined options entries and identified the Jan 2027 $460 Call as the optimal strike for a long-dated LEAPS position. At that time, this contract was out-of-the-money (OTM), trading at $57.75 per contract.

Fast forward to today, and the story has dramatically changed. The $460 strike call is now deep in-the-money (ITM), and the contract has surged to a mark price of $118.05. This means that anyone who acted on our analysis and followed the recommendation would be sitting on a 104% return — effectively doubling their money.

Let’s break down the numbers, compare the data, and analyze what this move means going forward.

Here’s the link to the earlier stock options analysis article on SNPS: Synopsys (SNPS) Stock Options Analysis – Oversold Opportunity with Staged LEAPS Entry

🔙 Original Setup (Then)

Back when we published the original call:

• Stock Price: ~$360
• 460 Strike Call (Jan 2027): Mark = $57.75
• Delta: ~0.51 (moderate exposure to stock moves)
• Implied Volatility (IV): ~41.4%
• Contract Status: Out-of-the-Money

📊 Current Update (Now)

Today, the numbers tell a very different story:

• Stock Price: ~$481 (after rebounding from a sharp dip to the $360s)
• 460 Strike Call (Jan 2027): Mark = $118.05
• Delta: ~0.69 (now strongly correlated to stock price)
• Implied Volatility (IV): ~42.6%
• Contract Status: In-the-Money

This contract, which was once a speculative OTM bet, has now become a high-delta ITM position, gaining intrinsic value as the stock recovered.

💰 Profit Calculation

Let’s put this in concrete numbers:

• Entry Price (Then): $57.75
• Current Price (Now): $118.05
• Profit per Contract: $118.05 − $57.75 = $60.30
• Dollar Gain per Contract: $60.30 × 100 = $6,030
• Percentage Gain: ($60.30 ÷ $57.75) × 100 ≈ 104% profit

✅ Result: A $5,775 investment per contract would now be worth $11,805.

📉 Chart Comparison: Then vs. Now

When we first recommended the trade, Synopsys’s stock price was in the ~$360s with RSI trending lower and MACD crossing down. The technicals suggested short-term weakness, but the long-term setup remained intact.

• Old Chart: RSI hovered near 40, MACD in bearish territory, price consolidating around $360.
• New Chart: RSI has rebounded from oversold lows (~16) back to ~44, MACD has turned bullish, and the stock is recovering from a capitulation sell-off.

📈 Options Chain Comparison

• Old Chain (Then): The 460 strike call was OTM, priced at $57.75 with Delta ~0.51.
• New Chain (Now): The same 460 strike call is ITM, priced at $118.05 with Delta ~0.69.

This shift from OTM to ITM is the critical transformation — the option not only held time value but also gained intrinsic value as the stock moved in its favor.

🔍 Updated Technical Analysis

Looking at the most recent charts:

• Daily RSI: ~44, recovering from oversold, suggesting more upside potential.
• Daily MACD: Bullish reversal cross, signaling momentum shift back to buyers.
• Weekly RSI/MACD: Stabilizing, with room for continuation if $500–520 levels are cleared.
• Volume: Heavy selling has been followed by strong accumulation, pointing toward institutional buying support.

Together, these indicators suggest that while the stock may consolidate in the near-term, the broader uptrend remains intact.

🚦 Takeaway

If you had followed the original analysis(Published September 10, 2025) and bought the Jan 2027 $460 Call when it was priced at $57.75, your contract would now be worth $118.05 — a +104% profit, or $6,030 per contract.

This trade illustrates two important lessons:

1. Patience pays in LEAPS: Long-dated contracts give room for volatility and allow the thesis to play out.
2. OTM can become ITM: Well-chosen OTM strikes can eventually transform into high-delta ITM positions, delivering outsized returns.

For traders who acted, congratulations — this trade doubled your capital. For those who missed it, the charts suggest more opportunities may be on the horizon.

✅ Disclaimer: This article is for informational and educational purposes only. It is not financial advice and should not be construed as a recommendation to buy or sell any security. Options trading involves substantial risk and is not suitable for every investor. Always do your own research and consult with a licensed financial advisor before making investment decisions.